Overview


According to FutureWise analysis the market for cancer biomarkers in 2023 is US$ 17.04 billion, and is expected to reach US$ 60.73 billion by 2031 at a CAGR of 17.2%.

Rising incidences of malignancies along with rising emphasis on developing targeted therapies is the key factor driving the market growth. Furthermore, the increasing awareness among healthcare personnel and patients regarding the importance of early malignancy diagnosis along with rising insistence for personalised medicine shall boost the cancer biomarkers market growth.

Diagnostic biomarkers are used for early diagnosis that has enabled doctors on making better decisions regarding treatment alternatives resulting into successful recoveries in less time. Additionally, the increased rate of regulatory approvals of advanced diagnostics and drugs related to cancer biomarkers is predicted to increase the rate of adoption. For example, Epigenomics Inc. in 2016 announced its Epi proColon was added as an epigenetic biomarker test by the Chinese government for screening colorectal cancer.

  • Thermo Fisher Scientific
  • Bio-Rad Laboratories
  • Roche Diagnostics
  • Qiagen N.V.
  • Illumina
  • GE Healthcare
  • Agilent Technologies
  • Biomérieux SA
  • MerckCo.
  • Abbott Laboratories
  • Becton
  • Dickinson and Company
  • Danaher Corporation
  • Myriad Genetics
  • Sysmex Corporation
  • Hologic
  • Quest Diagnostics

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Type

  • Protein Biomarkers
  • Genetic Biomarkers
  • Other Cancer Biomarkers (cell, viral, and carbohydrate biomarkers)

By Cancer Type

  • Breast Cancer
  • Lung Cancer
  • CRC
  • Prostate Cancer
  • Non-Hodgkin Lymphoma
  • Melanoma
  • Leukemia
  • Thyroid Cancer
  • Bladder Cancer
  • Kidney Cancer
  • Other Cancer Types

By Profiling Technology

  • OMICS Technologies
  • Proteomics
  • Genomics
    • NGS
    • PCR
  • Other OMICS Technologies
  • Imaging Technologies
    • Ultrasound
    • CT
    • MRI
    • PET
    • Mammography
  • Immunoassays
  • Cytogenetics
    • ISH
    • Other Cytogenetics-Based Tests
  • Bioinformatics

By Application

  • Diagnostics
  • Research and Development
  • Prognostics
  • Risk Assessment
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

The market is fragmented into type, cancer type, profiling technology, application and region. The type segment is categorised into protein biomarker and genetic biomarker. The genetic biomarker segment is anticipated to hold the largest cancer biomarkers market share, and this can be credited to the technological advancements in gene expression profiling, polymerase chain reaction and next generation sequencing for genetic biomarker diagnosis and discovery. The cancer type segment is categorised into breast cancer, lung cancer, CRC, prostate cancer, non-Hodgkin’s Lymhoma, melanoma, leukemia, thyroid cancer, bladder cancer, kidney cancer and other cancers. The lung cancer segment is predicted to account the largest cancer biomarkers market share. This growth can be credited to the rise in the number od newly registered cases of lung cancer. Companies are increasingly focusing on lung cancer biomarker research along with the rising comprehension of lung cancer morphology, rising emphasis om early cancer detection are boosting the proliferation of the market. The profiling technology segment is divided into OMICS technologies, proteomics, genomics. Bioinformatics is used for identifying biomedically relevant and powerful biomarkers. Data mining provides tools foe evaluating and interpreting the resulting predictions and models along with techniques for bolstering the prediction mechanisms. Such factors shall boost the proliferation of the market.

The North America region is expected to lead the market owing to the increased adoption of novel technologies such as next generation sequencing, growing research studies for developing and discovering advanced biomarkers and a strong presence of major pharmaceutical players. Furthermore, increased public and private investments and funds and rising usage of biomarkers for stratifying patients and developing drugs.

  • Tier 1 players-established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the global Cancer Biomarkers Market By Type, By Cancer Type, By Profiling Technology, By Application and By Region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America and Middle East and Africa
  • To record, evaluate and analyze competitive landscape mapping-product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization services offered are free of charge with purchase of any license of the report.
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
     

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1 . Years Considered for the Study
         3.2 . Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1 . Secondary Data
          1.1.1 . Key Data from Secondary Sources
         1.2 . Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Cancer Biomarkers Market Variables, Trends and Scope

    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework on Country Level
         6.1 . Reimbursement Framework
         6.2 . Standards and Compliances

  • 5.   Market Overview

    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Companion Animal Specialty Drugs Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework

  • 6.   Cancer Biomarkers Market Analysis tools

    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Type Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Type Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies

  • 7.   Cancer Biomarkers Market, By Type Historical Analysis 2017-2022 and Forecast 2023-2031 (USD million)

    •   1. Protein Biomarkers
        2. Genetic Biomarkers
        3. Other Cancer Biomarkers (cell, viral, and carbohydrate biomarkers)

  • 8.   Cancer Biomarkers Market, By Cancer Type Historical Analysis 2017-2022 and Forecast 2023-2031 (USD million)

    •           1. Breast Cancer
                2. Lung Cancer
                3. CRC
                4. Prostate Cancer
                5. Non-Hodgkin Lymphoma 
                6. Melanoma
                7. Leukemia
                8. Thyroid Cancer
                9. Bladder Cancer
               10. Kidney Cancer
               11. Other Cancer Types

  • 9.  Cancer Biomarkers Market, By Profiling Technology Historical Analysis 2017-2022 and Forecast 2023-2031 (USD million)

    •       1. OMICS Technologies 
            2. Proteomics
            3. Genomics
                3.1. NGS
                3.2. PCR
            4. Other OMICS Technologies
            5. Imaging Technologies
                5.1. Ultrasound
                5.2. CT
                5.3. MRI
                5.4. PET
                5.5. Mammography
            6. Immunoassays
            7. Cytogenetics
                7.1. ISH
                7.2. Other Cytogenetics-Based Tests
            8. Bioinformatics   

  • 10.  Cancer Biomarkers Market, By Application Historical Analysis 2017-2022 and Forecast 2023-2031 (USD million)

    •      1. Diagnostics
           2. Research and Development 
           3. Prognostics
           4. Risk Assessment
           5. Others    

  • 11.  North America Cancer Biomarkers Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •         1. Introduction
              2. Historical Market Size (USD Mn) Analysis By Country, 2017-2022
                  2.1. U.S.
                  2.2. Canada
                  2.3. Mexico 
                  2.4. Rest of North America
             3. Market Size (USD Mn) Forecast for North America 2023-2031

  • 12.  Latin America Cancer Biomarkers Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •          1. Introduction
               2. Regional Market Trends
               3. Historical Market Size (US$ Mn) Analysis By Country, 2017-2022
                   3.1. Brazil
                   3.2. Venezuela
                   3.3. Argentina
                   3.4. Rest of Latin America
               4. Market Size (US$ Mn) Forecast for Latin America 2023-2031

  • 13.  Europe Cancer Biomarkers Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •          1. Introduction
               2. Historical Market Size (US$ Mn) Analysis By Country, 2017-2022
                   2.1. Germany
                   2.2. U.K
                   2.3. France
                   2.4. Italy
                   2.5 Switzerland
                   2.6. Spain
                   2.7. Russia
                   2.8. Poland
                   2.9. Rest of Western Europe
               3. Market Size (US$ Mn) Forecast for North America 2023-2031

  • 14.  Asia Pacific Cancer Biomarkers Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •             1. Introduction
                  2. Historical Market Size (USD Mn) Analysis By Country, 2017-2022
                       2.1. Japan
                       2.2. China
                       2.3. Singapore
                       2.4. Korea         
                       2.5. India
                       2.6. Australia and New Zealand
                       2.7. ASEAN
                       2.8. Rest of Asia Pacific
                    3. Market Size (US$ Mn) Forecast for North America 2023-2031

  • 15.  Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •     1. Introduction
          2. Historical Market Size (USD Mn) Analysis By Country, 2017-2022
              2.1. GCC
              2.2. Israel
              2.3. South Africa
              2.4. Rest of MEA
          3. Market Size (US$ Mn) Forecast for MEA 2023-2031

  • 16.  Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Type and Technology Portfolio, Financial Layouts)

    •          1. Thermo Fisher Scientific
                   1.1. Company Overview (HQ, Business Segments, Employee Strength)
                   1.2. Product Portfolio
                   1.3. SWOT Analysis
                   1.4. Financial Overview
                   1.5. Strategic Overview
               2. Bio-Rad Laboratories
                   2.1. Company Overview (HQ, Business Segments, Employee Strength)
                   2.2. Product Portfolio
                   2.3. SWOT Analysis
                   2.4. Financial Overview
                   2.5. Strategic Overview
               3. Roche Diagnostics
                   3.1. Company Overview (HQ, Business Segments, Employee Strength)
                   3.2. Product Portfolio
                   3.3. SWOT Analysis
                   3.4. Financial Overview
                   3.5. Strategic Overview
               4. Qiagen N.V.
                   4.1. Company Overview (HQ, Business Segments, Employee Strength)
                   4.2. Product Portfolio
                   4.3. SWOT Analysis
                   4.4. Financial Overview
                   4.5. Strategic Overview
               5. Illumina
                   5.1. Company Overview (HQ, Business Segments, Employee Strength)
                   5.2. Product Portfolio
                   5.3. SWOT Analysis
                   5.4. Financial Overview
                   5.5. Strategic Overview
               6. GE Healthcare
                   6.1. Company Overview (HQ, Business Segments, Employee Strength)
                   6.2. Product Portfolio
                   6.3. SWOT Analysis
                   6.4. Financial Overview
                   6.5. Strategic Overview
               7. Agilent Technologies
                   7.1. Company Overview (HQ, Business Segments, Employee Strength)
                   7.2. Product Portfolio
                   7.3. SWOT Analysis
                   7.4. Financial Overview
                   7.5. Strategic Overview
               8. Biomérieux SA.
                   8.1. Company Overview (HQ, Business Segments, Employee Strength)
                   8.2. Product Portfolio
                   8.3. SWOT Analysis
                   8.4. Financial Overview
                   8.5. Strategic Overview    
               9. Merck & Co.
                   9.1. Company Overview (HQ, Business Segments, Employee Strength)
                   9.2. Product Portfolio
                   9.3. SWOT Analysis
                   9.4. Financial Overview
                   9.5. Strategic Overview
              10. Abbott Laboratories
                   10.1. Company Overview (HQ, Business Segments, Employee Strength)
                   10.2. Product Portfolio
                   10.3. SWOT Analysis
                   10.4. Financial Overview
                   10.5. Strategic Overview
             11. Becton, Dickinson and Company
                   11.1. Company Overview (HQ, Business Segments, Employee Strength)
                   11.2. Product Portfolio
                   11.3. SWOT Analysis
                   11.4. Financial Overview
                   11.5. Strategic Overview
             12. Danaher Corporation
                   12.1. Company Overview (HQ, Business Segments, Employee Strength)
                   12.2. Product Portfolio
                   12.3. SWOT Analysis
                   12.4. Financial Overview
                   12.5. Strategic Overview
             13. Myriad Genetics
                   13.1. Company Overview (HQ, Business Segments, Employee Strength)
                   13.2. Product Portfolio
                   13.3. SWOT Analysis
                   13.4. Financial Overview
                   13.5. Strategic Overview
             14. Sysmex Corporation
                   14.1. Company Overview (HQ, Business Segments, Employee Strength)
                   14.2. Product Portfolio
                   14.3. SWOT Analysis
                   14.4. Financial Overview
                   14.5. Strategic Overview
             15. Hologic
                   15.1. Company Overview (HQ, Business Segments, Employee Strength)
                   15.2. Product Portfolio
                   15.3. SWOT Analysis
                   15.4. Financial Overview
                   15.5. Strategic Overview
             16. Quest Diagnostics
                   16.1. Company Overview (HQ, Business Segments, Employee Strength)
                   16.2. Product Portfolio
                   16.3. SWOT Analysis
                   16.4. Financial Overview
                   16.5. Strategic Overview

  • 17.  Pre and Post COVID-19 Impact

    •         1. Positive influence on the healthcare industry
              2. The financial disruption of the manufacturing sector
              3. Impact of COVID-19 on emerging companies
              4. Significant mandates in the healthcare regulations initiated by
                   administrations
              5. The overall economic slowdown of the developing and developed nations

  • 18.  Competitive Intelligence and Competitive Matrix

    •          1. Competitive Intelligence
               2. Competitive Matrix

  • 19.  Major Deals and Strategic Alliances Analysis

    •       1. Joint ventures
            2. Mergers and acquisitions              
            3. Licensing and partnerships
            4. Technology Collaborations
            5. Strategic Divestments
            6. Market Entry Strategies

  • 20.  Relevant Case Studies and Latest News Updates

    •   

  • 21.  Key Market Takeaway Points from the Market Analysts at Future Market Analytics

    •   


Ask for Discount
Buy Now
Customize This Report
  • We Offer Special Discounts for start-ups, NGOs, and Educational & Research institutions.

Need Assistance

  • UK : +44 141 628 9353
  • US : +1 347 709 4931

What you get

  • Excel Dataset
  • Market Overview
  • Infographics
  • PowerPoint Presentation
  • PDF Report

What's included

  • Consumer Perception and Procurement
  • Market Data Forecast
  • Competitive Analysis
  • Risks and Opportunity Assessment
  • Market Trends and Dynamics
Partner

Our Clients

image0
image1
image2
image3
image4
image5
image6
image7
image8
image9
image10
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11